Tag:
ponatinib
Latest Headlines
Latest Headlines
Ariad's ponatinib takes center stage with promising pivotal leukemia data
Ariad Pharmaceuticals ( $ARIA ) took center stage at the big American Society of Hematology (ASH) meeting over the weekend with interim pivotal data demonstrating that close to half of all chronic
Ariad CEO vows that company "is not for sale"
Ariad Pharmaceuticals CEO Harvey Berger has a message for investors: "The company ( $ARIA ) is not for sale." It is, though, in partnership talks regarding its leukemia drug ponatinib. Ariad wants an
